AppointmentNervio appoints Dr. Richard Vogel as US CEO
Appointment
Nervio appoints Dr. Richard Vogel as US CEO
Nervio has created an AI-based neurophysiologist support system. Capable of imitating the expert’s analytical thought process, the software took five years, dozens of neurophysiologists and thousands of surgeries to develop.
Dr. Richard Vogel, an internationally respected leader in the field of neurophysiological monitoring, has joined Nervio as its U.S. CEO. The company’s U.S. operations are set to continue expanding to answer market interest while maintaining an R&D center in Israel.
Nervio has developed a novel AI-based neurophysiology monitoring technology. The company is currently raising its post-Seed round supplemented by a large grant from the Israel Innovation Authority.
Thousands of patients who undergo spine surgery every day are monitored real-time by neurophysiologists to minimize the risk of paralysis. The complex practice involves identifying disruptions in electrical conduction along the spinal cord using designated systems. However, these experts are being stretched thin by a growing number of procedures and staffing strains.
“Spine surgery volumes are expected to increase by as much as 40% over the next 10 years,” said Dr. Vogel, who also serves as president of the American Society of Neurophysiological Monitoring. “Neurophysiologists need innovative technology to support their current workload while maintaining high quality patient care in the context of increasing global demand.”
Nervio has created an AI-based neurophysiologist support system. Capable of imitating the expert’s analytical thought process, the software took five years, dozens of neurophysiologists and thousands of surgeries to develop. The brainchild of brothers Nir and Dr. Omer Zarchi, head of neuromonitoring services at a major medical center, the artificial intelligence technology was intended to reduce his team’s workload while ensuring no irregular signal goes unnoticed.
“Major technological advancements are exceedingly rare in neuromonitoring, and the field is ripe for disruption. Nervio's technology represents the most significant advancement in the history of this profession,” Dr. Vogel said, adding that “The ability to help lead a movement that will bring much-needed support to the workforce while optimizing patient care is attractive.”
